1 in 5 dogs suffer in silence from canine osteoarthritis (OA)1 – a chronic, progressive disease. Early diagnosis and intervention can help reduce discomfort and disrupt the progressive cycle of multidimensional deterioration.2
While OA can occur at any stage in a dog’s life, there are factors that can increase risk
Dogs don't always show overt signs of pain, so being alert to subtle behavioral changes is critical
Treatment for canine OA requires a multimodal approach
Specifically targets the EP4 receptor, the primary mediator of canine OA pain and inflammation4
Galliprant’s mode of action targets canine OA pain and inflammation while reducing the impact on GI, kidney and liver homeostasis 4, 5
No labeled requirement for serum biochemical evaluation makes way for flexibility in appropriate long-term monitoring*
*If Galliprant is used long-term, appropriate monitoring is recommended.
Find support through our resources to stage, diagnose, and treat OA.Discover Our Resources
Diagnose, stage and monitor OA with the Canine Osteoarthritis Staging Tool (COAST).
Feel inspired by the stories of veterinarians making a meaningful impact in the lives of their patients and their families.
Galliprant is a non-COX-inhibiting NSAID that delivers targeted, effective pain relief from the earliest diagnosed stages of OA.2* Start managing OA pain with Galliprant.
*The safe use of Galliprant has not been evaluated in dogs younger than 9 months of age and less than 8 lbs (3.6 kg)
Serving animals and caregivers since 1954
Products sold in over 90 countries
At Elanco, we provide those who raise and care for animals with solutions that empower them to advance a vision of food and companionship enriching life.
Galliprant is an NSAID that controls pain and inflammation associated with osteoarthritis in dogs.
Not for use in humans. For use in dogs only. Keep this and all medications out of reach of children and pets. Store out of reach of dogs and other pets in a secured location in order to prevent accidental ingestion or overdose. Do not use in dogs that have a hypersensitivity to grapiprant. If Galliprant is used long term, appropriate monitoring is recommended. Concomitant use of Galliprant with other anti-inflammatory drugs, such as COX-inhibiting NSAIDs or corticosteroids, should be avoided. Concurrent use with other anti-inflammatory drugs or protein-bound drugs has not been studied. The safe use of Galliprant has not been evaluated in dogs younger than 9 months of age and less than 8 lbs (3.6 kg), dogs used for breeding, pregnant or lactating dogs, or dogs with cardiac disease. The most common adverse reactions were vomiting, diarrhea, decreased appetite, and lethargy. Click here for full prescribing information.
Contact your Elanco or distributor representative, or call Elanco (1-888-545-5973) to discover how you can incorporate Galliprant into your canine OA protocol today.